Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

  • Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins
  • Clinical Session Expanded to Include Neuralink
  • Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2 nd Annual Spinal Cord Injury Investor Symposium ("2 nd SCIIS"). The 2 nd SCIIS aims to accelerate development in SCI research and treatments by bringing together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived experience, patient and community advocacy organizations, and the investment community, in order to discuss perspectives on current and future treatment alternatives, impact and support SCI disease awareness and clinical trial participation through the implementation of patient appropriate clinical endpoints, and broaden awareness of and investment of capital into SCI.

"Through our initiatives to raise awareness and increase collaboration in the field of spinal cord injury, we have encountered an enthusiastic response to this conference from a diverse and innovative group of companies and other stakeholders. While each of us has a preferred approach to how we can best support individuals living with SCI, common hurdles remain and this conference aims to provide a forum for collaborative problem-solving, as well serving as a one-stop educational opportunity for investors interested in this space," stated Brian M. Culley, Lineage CEO. "We are excited to add a BCI-focused clinical session this year with the inclusion of Neuralink and several additional corporate presenters. We invite investors and others to register to join us in person in San Diego on June 26 and 27 for this unique coming together of a forward-thinking group of leaders in SCI product development."

Current confirmed speakers and moderating healthcare analysts (subject to change):

Joseph Pantginis, Ph.D. Director of Research, Managing Director, Equity Research, H.C. Wainwright & Co., Inc .

Current presenters (subject to change):

- California Institute for Regenerative Medicine (CIRM)

- Clinical companies

- Preclinical companies

- Additional presenters

The 2 nd Annual Spinal Cord Injury Investor Symposium will be held in-person, on June 26 and 27, 2024, in the Duane Roth Auditorium at the Sanford Consortium for Regenerative Medicine in La Jolla, CA. Advance conference registration is required. For more information, please visit www.scisymposium.com or follow the event on X/Twitter @SCISymposium .

About Spinal Cord Injuries

A spinal cord injury occurs when the spinal cord is subjected to a severe crush or contusion and frequently results in severe functional impairment, including limb paralysis, aberrant pain signaling, and loss of bladder control and other body functions. There are approximately 18,000 new spinal cord injuries annually in the U.S. The cost of a lifetime of care for a severe spinal cord injury can be as high as $5 million.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel or "off-the-shelf," cell therapies to address unmet medical needs. Lineage's programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient's functional activity. Lineage's neuroscience focused pipeline currently includes: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed in collaboration with Eterna Therapeutics Inc. For more information, please visit www.lineagecell.com or follow the company on X/Twitter @LineageCell .

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as "believe," "aim," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "can," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "tend to," or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to: the potential effect of the 2 nd SCIIS, including accelerating development in SCI research and treatment, and raising SCI disease awareness. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, but not limited to, the following risks: that engagement with patients and the advocacy community may not lead to improvements in patient outcomes; and those risks and uncertainties inherent in Lineage's business and other risks discussed in Lineage's filings with the Securities and Exchange Commission (SEC). Lineage's forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading "Risk Factors" in Lineage's periodic reports with the SEC, including Lineage's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC and its other reports, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
( ir@lineagecell.com )
(442) 287-8963

LifeSci Advisors
Daniel Ferry
( daniel@lifesciadvisors.com )
(617) 430-7576

Russo Partners – Media Relations
Nic Johnson or David Schull
( Nic.johnson@russopartnersllc.com )
( David.schull@russopartnersllc.com )
(212) 845-4242

News Provided by Business Wire via QuoteMedia

LCTX:US
The Conversation (0)
Lineage to Present at 2024 BIO International Convention

Lineage to Present at 2024 BIO International Convention

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company's CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tuesday June 4 th , 2024, at 2:30pm in Theater 3. Company representatives are also hosting meetings with potential partners and collaborators to discuss opportunities for strategic alliances across Lineage's novel pipeline of cell therapy transplant programs. The BIO International Convention is the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world, and is taking place June 3-6, 2024, at the San Diego Convention Center in San Diego, CA.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

  • Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins
  • Clinical Session Expanded to Include Neuralink
  • Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2 nd Annual Spinal Cord Injury Investor Symposium ("2 nd SCIIS"). The 2 nd SCIIS aims to accelerate development in SCI research and treatments by bringing together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived experience, patient and community advocacy organizations, and the investment community, in order to discuss perspectives on current and future treatment alternatives, impact and support SCI disease awareness and clinical trial participation through the implementation of patient appropriate clinical endpoints, and broaden awareness of and investment of capital into SCI.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

  • Established New Services Agreement with Genentech to Support Ongoing Development of the OpRegen ® Program
  • Long-Term Visual Benefits from a Single Administration with OpRegen Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit
  • OpRegen Preclinical Results Presented at 2024 Association for Research in Vision and Ophthalmology Annual Meeting
  • OPC1 Clinical Study Start Up Preparation Underway
  • Received CIRM Grant to Support 2 nd Annual SCI Investor Symposium
  • Appointed Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its first quarter 2024 financial and operating results and will host a conference call at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.

"The quarter was highlighted by significant milestones and data updates on our lead program," stated Brian M. Culley, Lineage CEO. "A key area of attention for investors is our partnership with Roche and Genentech, and we are pleased to announce a new services agreement which reflects an additional commitment by Genentech for the benefit of the OpRegen program. We believe this agreement will enable our partners to take advantage of our cell transplant expertise to more fully investigate the promising potential of the OpRegen program and do so in a cost-effective manner. We also are planning to bring our second cell transplant program, OPC1, into the clinic this year for a condition with growing awareness of its unmet need and commercial opportunity. Lastly, we continue to build value through the advancement of our early-stage pipeline, which can help create value by capitalizing on the continued validation of our cell transplant approach."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

  • Established New Services Agreement with Genentech to Support Ongoing Development of the OpRegen ® Program
  • Long-Term Visual Benefits from a Single Administration with OpRegen Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit
  • OpRegen Preclinical Results Presented at 2024 Association for Research in Vision and Ophthalmology Annual Meeting
  • OPC1 Clinical Study Start Up Preparation Underway
  • Received CIRM Grant to Support 2 nd Annual SCI Investor Symposium
  • Appointed Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its first quarter 2024 financial and operating results and will host a conference call at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.

"The quarter was highlighted by significant milestones and data updates on our lead program," stated Brian M. Culley, Lineage CEO. "A key area of attention for investors is our partnership with Roche and Genentech, and we are pleased to announce a new services agreement which reflects an additional commitment by Genentech for the benefit of the OpRegen program. We believe this agreement will enable our partners to take advantage of our cell transplant expertise to more fully investigate the promising potential of the OpRegen program and do so in a cost-effective manner. We also are planning to bring our second cell transplant program, OPC1, into the clinic this year for a condition with growing awareness of its unmet need and commercial opportunity. Lastly, we continue to build value through the advancement of our early-stage pipeline, which can help create value by capitalizing on the continued validation of our cell transplant approach."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

  • Established New Services Agreement with Genentech to Support Ongoing Development of the OpRegen ® Program
  • Long-Term Visual Benefits from a Single Administration with OpRegen Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit
  • OpRegen Preclinical Results Presented at 2024 Association for Research in Vision and Ophthalmology Annual Meeting
  • OPC1 Clinical Study Start Up Preparation Underway
  • Received CIRM Grant to Support 2 nd Annual SCI Investor Symposium
  • Appointed Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its first quarter 2024 financial and operating results and will host a conference call at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.

"The quarter was highlighted by significant milestones and data updates on our lead program," stated Brian M. Culley, Lineage CEO. "A key area of attention for investors is our partnership with Roche and Genentech, and we are pleased to announce a new services agreement which reflects an additional commitment by Genentech for the benefit of the OpRegen program. We believe this agreement will enable our partners to take advantage of our cell transplant expertise to more fully investigate the promising potential of the OpRegen program and do so in a cost-effective manner. We also are planning to bring our second cell transplant program, OPC1, into the clinic this year for a condition with growing awareness of its unmet need and commercial opportunity. Lastly, we continue to build value through the advancement of our early-stage pipeline, which can help create value by capitalizing on the continued validation of our cell transplant approach."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
VIDEO - Invest Yukon: Critical Mineral Development in The Yukon

VIDEO - Invest Yukon: Critical Mineral Development in The Yukon

Invest Yukon - Hon Ranj Pillai, Yukon's Premier highlights the key critical minerals conversation and the promising economic future for Yukon. Western Copper and Gold (TSX: WRN) (NYSE American: WRN) emphasizes that as the demand for critical minerals intensifies, they are well positioned to meet the needs of the territory, Canada and global demand, as a leading developer in Canada. With a robust focus on advancing major projects, the company is set to significantly contribute to the critical metals supply chain. Supported by favorable governmental policies and an experienced management team, Western Copper and Gold is poised to become a cornerstone in the mining sector, driving economic growth and sustainability. Stillwater Critical Minerals (TSXV: PGE) explores a new region that reveals critical mineral potential over a district-scale land package.

Invest Yukon
Yukon Mining Alliance
investyukon.ca

Founded in 2009, Yukon Mining Alliance ("YMA"), the globally recognized Invest Yukon brand - is a strategic industry alliance of Yukon's leading exploration, development, and mining companies, focused on creating innovative capital attraction initiatives to promote Yukon's competitive advantages as a top mineral investment jurisdiction, its member companies and their Yukon-based projects. YMA's initiatives include international investment focused conferences, events, and campaigns in the North American, European, and global financial markets.

About BTV - Business Television:
For over 25 years, BTV has been a capital markets focused TV production and Digital Marketing Agency. BTV helps companies increase their brand awareness to a national retail and institutional investor audience, combining unique content creation and major distribution services on top tier networks including Bloomberg, CNBC, FOX Business News and financial sites. The BTV suite of strategic products include: BTV- Business Television Show, CEO Clips™, TV Branding Ads, Digital, Lead Gen, Social and Direct Email Marketing Campaigns that reach investors where they research and live on-air and online.

Discover Investment Opportunities

www.b-tv.com/theagency

Contact: Trina Schlingmann (604) 664-7401 x 5 trina@b-tv.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/213962

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Canadian Critical Minerals Receives Update on Drill Results from Thierry Copper Project

Canadian Critical Minerals Receives Update on Drill Results from Thierry Copper Project

Canadian Critical Minerals Inc. (TSXV: CCMI) (OTCQB: RIINF) ("CCMI" or the "Company") has received results from the remaining five drill holes at the Thierry Copper Project near Pickle Lake, Ontario that were drilled by CCMI in July 2023 as part of a 2,600 metre drill program. The Thierry Copper Project is 100% owned by Cuprum Corp. CCMI owns 23.2 million shares of Cuprum and is the second largest shareholder with approximately 30% of the issued shares of Cuprum. Orecap Invest Corp. is the largest shareholder owning 29.5 million shares of Cuprum.

A complete review of the drill results has been disclosed by Orecap Invest Corp. earlier this morning and is available on Sedar Plus in their press release dated June 20, 2024, or on their website at www.orecap.ca. Further to CCMI's disclosure of September 20, 2023, which is available on Sedar Plus, the results are as good or better than expected.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Aston Bay Holdings Closes Final Tranche of Non-brokered Private Placement for $4,130,460 Total Proceeds

Aston Bay Holdings Closes Final Tranche of Non-brokered Private Placement for $4,130,460 Total Proceeds

THIS PRESS RELEASE IS NOT FOR DISTRIBUTION IN THE UNITED STATES OR TO U.S. NEWS AGENCIES

Aston Bay Holdings Ltd. (TSX-V:BAY)(OTCQB:ATBHF) ("Aston Bay" or the "Company") is pleased to announce that it has closed a final tranche of the Company's non-brokered private placement, previously announced on April 24, 2024 (the "Offering"). Pursuant to the final tranche of the Offering, the Company has issued 230,000 non-flow through units (each a "Unit") at a price of $0.12 per Unit (the "LIFE Offering") and 3,900,000 flow through shares (each an "FT Share") at a price of $0.15 per FT Share, for aggregate gross proceeds of $612,600. The closing is subject to final acceptance of the TSX Venture Exchange

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Grid Battery Metals Completes Phase 2 of its 2024 Clayton Valley Project 2024 Exploration Plan

Grid Battery Metals Completes Phase 2 of its 2024 Clayton Valley Project 2024 Exploration Plan

(TheNewswire)

Grid Battery Metals Inc..

Coquitlam, BC TheNewswire - June 20, 2024 - Grid Battery Metals Inc. (the "Company" or "Grid") ( TSXV: CELL, OTCQB: EVKRF FRA: NMK2 ) is pleased to announce the conclusion of a second phase of soil samples and the construction of a geologic model incorporating mapped geology, magnetotelluric (MT) geophysics, and soil geochemistry. Grid's exploration team has determined that a multilayered approach to drill targets would improve the chances of intercepting lithium bearing brines.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
VIZSLA COPPER ANNOUNCES CLOSING OF BROKERED PRIVATE PLACEMENT FOR GROSS PROCEEDS OF C$5.46 MILLION

VIZSLA COPPER ANNOUNCES CLOSING OF BROKERED PRIVATE PLACEMENT FOR GROSS PROCEEDS OF C$5.46 MILLION

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /

Vizsla Copper Corp. (TSXV: VCU) (OTCQB: VCUFF) (" Vizsla Copper " or the " Company ") is pleased to announce the closing of its previously announced marketed best efforts brokered private placement (the " Offering ") for aggregate gross proceeds of approximately C$5,463,000 . Under the Offering, the Company sold 9,379,088 units of the Company (the " Units ") at a price of C$0.11 per Unit and 36,923,800 flow-through units of the Company (the " FT Units ", and together with the Units, the " Offered Units ") at a price of C$0.12 per FT Unit.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Canadian North Resources Inc. Announces Results of Annual General Meeting

Canadian North Resources Inc. Announces Results of Annual General Meeting

Canadian North Resources Inc. ("CNRI" or "the Company," TSXV: CNRI; OTCQX: CNRSF; FSE: EO0 (E-O-zero)) is pleased to announce the voting results for the election of its Board of Directors at its Annual and Special Meeting of Shareholders held on June 18, 2024, in Mississauga, Ontario. A total of 75,369,669 common shares were voted at the Meeting, representing 65.81% of the common shares outstanding (114,527,617).

Shareholders approved the re-election of all Directors as listed in the Management Information Circular dated May 28, 2024, and the reappointment of MNP LLP, Chartered Professional Accountants, as auditors of the Company at a remuneration to be fixed by the directors. In addition, the resolution to ratify and approve the Company's Stock Option Plan was passed.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×